Galena Biopharma (GALE) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Galena Biopharma (GALE) PT Cut to $1 at Maxim Group, Focus on GALE-401
August 10, 2016 7:20 AM EDTMaxim Group analyst Jason McCarthy cut his price target on Galena Biopharma (NASDAQ: GALE) to $1.00 (from $2.00) but maintained a Buy rating as the company works its way out of the penalty box.
McCarthy highlighted:
Galena reported 2Q16 with net income of $5.4M, resulting from a combination of decreased warrant liabilities (due to a decline in stock price), as well as purchase price liability for NeuVax (due to PRESENT termination), offset by $9.3M in operating expenses. The company... More
